Here are ten small-cap, publicly traded companies that are incorporating cutting-edge AI technology into healthcare!

Ten small-cap, publicly traded companies using cutting edge Ai in to enhance healthcare!

1. iCAD Inc. (NASDAQ: ICAD)

   iCAD develops advanced AI solutions for early cancer detection and therapy. Their ProFound AI® platform assists radiologists by improving the accuracy and efficiency of breast cancer detection in mammography and digital breast tomosynthesis. The technology uses deep learning algorithms to analyze images and highlight areas of concern, aiding in clinical decision-making.

2. BioXcel Therapeutics Inc. (NASDAQ: BTAI)

   BioXcel Therapeutics leverages artificial intelligence to identify and develop new medicines in neuroscience and immuno-oncology. Their proprietary AI platform, EvolverAI, analyzes vast datasets to discover novel drug candidates and repurpose existing drugs, accelerating the drug development process and reducing costs.

3. Predictive Oncology Inc. (NASDAQ: POAI)

   Predictive Oncology uses AI and machine learning to develop personalized cancer therapies. Their subsidiary, Helomics, utilizes a comprehensive tumor profiling platform powered by AI to predict how tumors will respond to various treatments. This approach aims to improve patient outcomes by tailoring therapies to individual tumor characteristics.

4. Lantern Pharma Inc. (NASDAQ: LTRN)

   Lantern Pharma employs AI-driven genomics and biomarker data to streamline the development of oncology drugs. Their proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), uses machine learning to identify patient groups most likely to benefit from specific therapies, enhancing the efficiency of clinical trials and increasing the likelihood of regulatory approval.

5. Exscientia plc (NASDAQ: EXAI)

   Exscientia is a pharmatech company specializing in AI-driven drug discovery. Their end-to-end platform integrates AI algorithms with experimental capabilities to design and optimize novel drug candidates rapidly. Exscientia has been successful in advancing multiple AI-designed molecules into clinical trials, demonstrating the potential of AI in accelerating pharmaceutical innovation.

6. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX)

   Recursion Pharmaceuticals uses AI and machine learning to accelerate drug discovery by integrating experimental biology and chemistry with advanced computational tools. Their platform rapidly identifies potential therapeutics across various disease areas, aiming to shorten the drug development timeline.

7. Renalytix plc (NASDAQ: RNLX)

   Renalytix develops AI-enabled diagnostics for kidney disease. Their KidneyIntelX™ platform uses machine learning algorithms to assess the risk of progressive decline in kidney function, aiding in early intervention and personalized treatment plans to improve patient outcomes.

8. Nanox Imaging Ltd. (NASDAQ: NNOX)

   Nanox is developing a novel digital X-ray source and AI-powered imaging systems. Their technology aims to make medical imaging more accessible and affordable globally. The integration of AI enhances image analysis, potentially enabling earlier detection of diseases.

9. Butterfly Network, Inc. (NYSE: BFLY)

   Butterfly Network has created a handheld, smartphone-connected ultrasound device powered by AI. Their Butterfly iQ+ uses AI to assist clinicians in acquiring and interpreting ultrasound images, making diagnostic imaging more accessible in various healthcare settings.

10. DarioHealth Corp. (NASDAQ: DRIO)

    DarioHealth provides digital therapeutics solutions for chronic conditions. Their AI-driven platform offers personalized health management tools for diabetes, hypertension, and weight management. By utilizing data analytics and AI, they aim to improve patient engagement and outcomes.

These companies are at the forefront of integrating artificial intelligence into healthcare, aiming to improve diagnostics, personalize treatments, and accelerate drug discovery processes. Investing in these firms involves risks typical of small-cap stocks, such as higher volatility and potential liquidity issues, so thorough due diligence is recommended.

Discl: 

We own shares of only one of these companies at this writing, however, are doing more due diligence on several others!

Update: Sept 18th 2024

We now own shares of: - RXRX ICAD NNOX and BFLY

Related Articles:

The partnership between Microsoft and Adaptive Biotechnologies represents a convergence of biotechnology, Ai, medicine and advanced computing, to unlock the secrets of the immune system.

Target: Cancerous tumors- TransCode's technology is designed to target dysregulated microRNAs implicated in cancer progression, metastasis, and resistance to existing therapies.

These "Microcap" companies operate in innovative and emerging sectors, which may position them for significant growth.

From promising cancer treatments to new and improved imaging, ultrasould and diagnosis, Ai is enhancing these microcaps!

 Promising Microcap stocks in Healthcare, Quantum computing, Ai, Lidar, Nanotech, imaging & more!

These "Microcap" companies operate in innovative and emerging sectors, which may position them for significant growth.

--------------------------------------------------------------------------------------------------------

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology

In treating Cancerous tumors, TransCode's technology is designed to target cancer progression, metastasis, and resistance to existing therapies.

"Genius" by Verses , a "super smart brain", developed by a team of 25 PHD's including world renowned Neuro Scientist, Karl Friston

An Analysis of Plug Power Inc.: Market Position, Technological Edge, Infrastructure, Financials, Analyst Coverage, Key Contracts, and Leadership in the Hydrogen Market

Investing in Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) at the intersection of biotechnology and advanced computational methods.

Here are ten small-cap, publicly traded companies that are incorporating cutting-edge AI technology into healthcare!

Enovix Corp holds over 130 issued patents, covering various aspects of their innovative battery technology.

IONQ distinguishes itself from other quantum computing companies through several key advantages that make it a compelling choice for investors, researchers, and organizations:

IBC Advanced Alloy Moves to Broaden US Institutional Investor Outreach

IBC Advanced Alloys Corp.

TSX VENTURE : IB
OTCQX : IAALF

November 18, 2014 09:00 ET

IBC Advanced Alloys Engages Stonegate Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 18, 2014) - IBC Advanced Alloys Corp. (TSX VENTURE:IB)(OTCQX:IAALF) announces that it has retained the services of Stonegate Inc. to provide investor relations services to the Company with a specific focus on the US small-cap institutional investment community.
Stonegate Inc. is a 40-year-old investor relations, research and investment banking firm based in Dallas, Texas. Its research covers companies in a variety of industries and is distributed to its wide network of institutional investors. Stonegate's primary focus is assisting small cap companies to achieve their capital markets objectives and to both increase and strengthen their institutional shareholder base.
Anthony Dutton, President and CEO of IBC commented, "With increasing interest from the aerospace and precision manufacturing sectors, now is the ideal time to introduce IBC to targeted US institutional investors. We understand their investment criteria, are confident we are meeting those criteria, and we believe Stonegate is a great fit for us because of their expertise in this sector. We look forward to working with them and have targeted early December for our first investor presentations."
In connection with the engagement, Stonegate will receive US$5,000 per month commencing November 17, 2014. The term of the agreement is six months and may be cancelled subsequently, in writing, with standard notice provisions. The agreement is subject to the acceptance of the TSX Venture Exchange.
About IBC Advanced Alloys Corp.
IBC is an integrated manufacturer and distributor of rare metals (beryllium) based alloys and related products serving a variety of industries including nuclear energy, automotive, telecommunications and a range of industrial applications. IBC has 80 employees and is headquartered in Vancouver, Canada with production facilities in Indiana, Massachusetts, Pennsylvania and Missouri. IBC is creating a dynamic global beryllium and advanced alloys company. IBC's common shares are traded on the TSX Venture Exchange under the symbol "IB" and the OTCQX under the symbol "IAALF."
This news release was prepared by management of IBC, which takes full responsibility for its contents. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of this news release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This disclosure contains certain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control including: the impact of general economic conditions in the areas in which the Company operates, industry conditions, changes in laws and regulations including the adoption of new environmental laws and regulations and changes in how they are interpreted and enforced, increased competition, the lack of availability of qualified personnel or management, limited availability of raw materials, fluctuations in commodity prices, foreign exchange or interest rates, stock market volatility and obtaining required approvals of regulatory authorities. In addition there are risks and uncertainties associated with manufacturing activities therefore the Company's future results, performance or achievements could differ materially from those expressed in these forward-looking statements. All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances.

Contact Information

IBC Advanced Alloys Corp.
Ian Tootill
Director of Corporate Communications
(604) 685-6263 ext. 110
itootill@ibcadvancedalloys.com
www.ibcadvancedalloys.com

The Howard Group Inc.
Dave Burwell / Brad Dryer
Toll Free: 1-888-221-0915 or (403) 221-0915
info@howardgroupinc.com

IBC on You Tube